FMP
Iterum Therapeutics plc
ITRM
NASDAQ
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
1.52 USD
-0.0251 (-1.65%)
About
ceo
Mr. Corey N. Fishman
sector
Healthcare
industry
Biotechnology
website
https://www.iterumtx.com
exchange
NASDAQ
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
CIK
0001659323
ISIN
IE000TTOOBX0
CUSIP
G6333L101
Address
Fitzwilliam Court
Phone
353 1 669 4820
Country
IE
Employee
14
IPO Date
May 25, 2018
Summary
CIK
0001659323
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
G6333L101
ISIN
IE000TTOOBX0
Country
IE
Price
1.52
Beta
2.36
Volume Avg.
624.16k
Market Cap
25.05M
Shares
-
52-Week
0.622-2.5
DCF
-1.04
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.52
P/B
-
Website
https://www.iterumtx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ITRM News
It looks like there's no news available.
